Objectives Metabolic syndrome (MS) is the concurrence of at least three of five medical conditions: obesity, high blood pressure, insulin resistance, high serum triglyceride (TG) and low serum high-density lipoprotein levels. While fibrates are used to treat disorders other than the lowering serum TG, the mechanism by which fibrates decrease MS has not been established. Methods In this study, wild-type and Ppara-null mice fed a medium-fat diet (MFD) were administered gemfibrozil and fenofibrate for 3 months respectively, to explore the effect and action mechanism. Key findings In Ppara-null mice, MFD treatment increased body weight, adipose tissue, serum TG and impaired glucose tolerance. These phenotypes were attenuated in two groups treated with gemfibrozil and fenofibrate. The STAT3 pathway was activated in adipose and hepatic tissues in positive control, and inhibited in groups treated with gemfibrozil and fenofibrate. The above phenotypes and inflammation were not observed in any wild-type group. In 3T3-L1 adipogenic stem cells treated with high glucose, STAT3 knockdown greatly decreased the number of lipid droplets. Conclusions Low dose of clinical fibrates was effective against MS development independent of PPARa, and this action was mediated by STAT3 signalling inhibition in adipose tissue and, to a lesser extent, in hepatic tissues.
Introduction
Metabolic syndrome (MS) is diagnosed by the concurrence of at least three of the following diseases: obesity, elevated blood pressure, insulin resistance, high serum triglyceride (TG) and low serum high-density lipoprotein cholesterol (HDL-C). In the last decade, the prevalence of MS has markedly increased. [1] Both the unadjusted prevalence and age-adjusted prevalence significantly increased according to NHANES III and NHANES 1999-2006 . [2] The MS events are closely related, and they frequently co-initiate and deteriorate in parallel. In MS patients, the risk of developing diabetes mellitus (DM) and cardiovascular diseases increased. [3] Morbidity and mortality associated with dyslipidaemia in DM patients was 2-8 times higher than those in non-DM patients. [4] Pharmacological agents for treating MS symptoms are often co-administered. Metformin and the glitazone drugs have been used to treat DM in patients with or without MS, [5, 6] while statins and fibrates are classical choices for atherogenic dyslipidaemia. However, when these agents were co-administered to treat MS symptoms, the toxicity risk is increased compared with single therapy. [1] Metabolic syndrome was associated with various inflammatory signalling cascades. When put on a high-fat diet (HFD, 60% kcal fat), IKK2 heterozygous mice developed obesity, but their glucose tolerance and basal glucose/insulin values improved, indicating a relationship between the NF-jB pathway and MS symptoms. [7] In JNK-deficient mice, treatment with HFD significantly decreased the body weight and protected against the development of insulin resistance. [8] Additionally, in both dietary and genetically obese mouse models, there was a significant increase in JNK activity in liver tissues. [9] These responses suggested that the JNK pathway was closely related to MS. In mice with hepatocyte-specific deletion of Janus kinase 2 (JAK2), HFD improved glucose-stimulated insulin secretion and increased the mass of pancreatic b-cells. [10] Disruption of JAK2 led to spontaneous steatosis and nonalcoholic fatty liver disease, which were considered as hepatic manifestations of MS. [11, 12] In mice fed high-fat diet, the STAT3 signalling inhibition by lycopene attenuated development of lipid accumulation, inflammation, insulin resistance and metabolic dysfunction. [13] In C57BL/6J mice treated with 30% fructose, when the JAK2/STAT3 was activated, the symptoms of NAFLD were improved. [14] In another mouse model treated with lipopolysaccharide, inhibiting STAT3 pathway led to alleviation of adipocyte inflammation. [15] These reports suggested that MS symptoms were associated with typical inflammation pathways NF-jB, JNK and STAT3. However, little is known which of the above pathways is critically important for MS development and treatment.
Clinically, fibrates are prescribed to treat dyslipidaemia due to increased TG or decreased HDL-C. [16] The beneficial effects of gemfibrozil, fenofibrate and bezafibrate for glucose metabolism disorders were reported in mouse, rat models and humans. [17] [18] [19] [20] Additionally, reduction in blood pressure is also associated with fibrate administration. [21] The in situ actions of fibrate drugs on vascular smooth muscle cells blood vessels and smooth muscles were recently reported. [21, 22] And the reduction in blood pressure was observed following fibrate treatment. [23, 24] Thus, besides the action of fibrates on lipid metabolism, the effects on glucose metabolism and blood pressure could be considered as a therapeutic option for MS. However, it was not established whether fibrates could inhibit MS development in an in vivo MS model.
Peroxisome proliferator-activated receptor a (PPARa) is a nuclear transcription factor regulating lipid metabolism in mammals. [25, 26] All the actions on cardiovascular system by fibrates are considered as downstream events of PPARa activation. In mice fed a diet enriched with hydrogenated coconut oil, hyperinsulinaemia was observed in wild-type mice, but not in Ppara-null mice. [27] In the Ppara-null mice treated with HFD, the concentrations of atherogenic lipoproteins were high, but insulin sensitivity, blood pressure and intimal lesion were all improved. [28] In a Ppara-null/Apoe-null mouse model, the absence of PPARa led to a greater suppression of endogenous glucose production as revealed by a hyperinsulinaemia clamp studies, indicating less insulin resistance in the absence of PPARa. [28] These studies suggest a role for PPARa in MS treatment, mechanism of which has not hitherto been explored.
In this study, an MS model was induced by MFD treatment to determine the role of PPARa in MS. Fenofibrate and gemfibrozil treatments were performed to observe the pharmacological actions of these PPARa agonists on MS. STAT3 was found to mediate the MS development and therapeutic actions by fibrates, which was validated in 3T3-L1 adipogenic stem cells using knockdown strategy.
Materials and Methods

Chemicals and reagents
Gemfibrozil, fenofibrate, Oil Red O, dexamethasone, 3-isobutyl-1-methylxanthine and bovine insulin were all obtained from Sigma-Aldrich (St. Louis, MO, USA). TC and TG assay kits were purchased from Ruiyuan Biotechnology (Ningbo, China). Antibodies against NFjB subunit p65 and active form phospho-p65 (p-p65), total STAT3 (t-STAT3), phospho-STAT3 (p-STAT3), phospho-JNK (p-JNK), phospho-ATF2 (p-ATF2) and GAPDH were acquired from Abcam (Cambridge, MA, USA). The reverse transcription kit and LightCycler 480 SYBR Green I Master Mix were obtained from Roche Diagnostics (Mannheim, Germany). Blood glucose meter test strips were bought from Johnson & Johnson Pharmaceuticals Ltd (New Brunswick, NJ, USA). Ultrapure water was freshly prepared using a Milli-Q50 SP Water System (Millipore Corporation, MA, USA). Medium-fat diet (MFD, 31% kcal fat) was obtained from SLACOM (Shanghai, China). All the other chemicals were of the highest grade available from commercial sources.
Animals and treatments
The wild-type and Ppara-null mice on the 129/Sv background were maintained under a standard 12-h light/ dark cycle with free access to water and a commercial diet. All mice were subject to acclimation for 7 days before the experiments. The procedures performed were in accordance with Institute of Laboratory Animal Resource Guidelines and the protocols approved by the Medical School of Ningbo University Animal Care and Use Committee. Both the wild-type and the Ppara-null mice were divided into four groups (n = 5), vehicle/ control (WT-Con, KO-Con), MFD/control (WT-MFD, KO-MFD), MFD/0.375% gemfibrozil (WT-MFD-G, KO-MFD-G) and MFD/0.075% fenofibrate (WT-MFD-F, KO-MFD-F). The treatment was continued for 3 months. The nutrition components of the MFD were shown below in Table S2 .
The body weights of all the mice were measured every week. Before the end of the experiment, an oral glucose tolerance test was performed. Specifically, after all mice were fasted for 12 h, the fasting blood glucose level was measured and the mice were orally challenged with a single dose of glucose solution (3 g/kg). During the test, the blood glucose was determined immediately after collection by tail bleeding every 30 min.
After the glucose tolerance test, the mice were allowed 3 days of recovery. Then, all mice were weighed and killed by asphyxiation after blood collection. Adipose and liver tissues were harvested and weighed to calculate liver index and adipose index. Liver and adipose sections were cut and fixed in 10% formalin solution, and the remainders were immediately frozen on dry ice and stored at À80°C.
Biochemical analysis and histopathological assessment
Total cholesterol and TG in serum were assayed by the Thermo Scientific Multiskan GO (Waltham, MA, USA). The measurements were carried out following protocols supplied with the kits. The liver tissues (50 mg) from different groups were homogenized by MagNA Lyser (Roche, Basel, Switzerland) in 150 ll physiological saline. The supernatant (80 ll) was used for assaying hepatic TC and TG by the same method as in the serum. The above determination of each marker was performed on the same 96-well plate to avoid systematic error. The concentrations of blood glucose were measured by use of a glucometer (Johnson & Johnson Ltd, New Brunswick, NJ, USA). Formalin-fixed liver and adipose tissues were dehydrated in alcohol and xylene following the standard procedures and embedded by paraffin for preparation of four-micrometre sections. After staining with haematoxylin and eosin, the liver sections were examined under a microscope. A total of 10 sections per preparation were imaged, and all images were analysed blindly. To indicate the cell size of the adipose tissues, the diameter of fat cells was measured by Image J.
qPCR and Western blot analysis
Processing of liver and adipose samples followed the previously published procedures. [29] The primer sequences, listed in Table S1 , were extracted from http://mouseprime rdepot.nci.nih.gov. A 5 ll PCR system was designed for the 384 plate that included 1 ll of total cDNA, 2.5 ll of LightCycler 480 SYBR Green I Master Mix, 0.2 ll of forward and reverse primer and 2 ll of nuclease-free water. The samples from eight groups (WT-Con/KO-Con, WT-MFD/ KO-MFD, WT-MFD-G/KO-MFD-G, WT-MFD-F/KO-MFD-F) for qPCR were determined in the same run on one 384-well plate. The procedures of Western blot analysis also followed a previous study by our group. [30] STAT3 knockdown in 3T3-L1 adipogenic stem cells 3T3-L1 adipogenic stem cells were cultured in high-glucose (4.5 g/l) DMEM containing 10% fetal bovine serum (FBS) and penicillin/streptomycin (both at 100 U/ml) at 37°C with 5% CO 2 . To induce differentiation, the cells were cultured for 2 days after confluence and then treated with culture medium supplemented with 1.0 lM dexamethasone, 0.5 mmol/l 3-isobutyl-1-methylxanthine and 5.0 lg/ml insulin for 48 h. The cells were cultured in DMEM/10% FBS supplemented with 5.0 lg/ml insulin for additional 6 days.
Two mouse Stat3 siRNAs (siStat3-1:
0 ) (GenePharma, Shanghai, China) were transfected into the cells using Lipofectamine RNAiMAX before induction of differentiation. GL3 siRNA (siGL3: 5 0 -CUUACGCUGAGUACUUCGATT-3 0 ) was used as a control. Seventy-two hours after induction, the cells were collected for Western blot analysis. After 8 days of induction, monolayers of differentiated 3T3-L1 adipocytes were washed twice with PBS and fixed with 4% paraformaldehyde for 30 min at room temperature. The cells were then stained with 0.5% Oil Red O in isopropanol for 1 h at room temperature. After staining, the cells were washed with 60% isopropanol and then with PBS. Finally, the stained lipid droplets were visualized and photographed using light microscopy.
Statistical analysis
All the data were expressed as the mean AE SD. The statistical analysis of biochemical markers and qPCR data was performed among wild-type groups and Ppara-null groups, respectively. No comparison between wild-type and Pparanull mice was made. SPSS 17.0 for Windows was used for the data analysis. Differences among multiple groups were tested using one-way analysis of variance followed by Dunnett's post hoc comparisons. Differences were considered significant when P < 0.05 and were marked with asterisks and carets in the graphs accordingly.
Results
Fibrates inhibit the MS phenotype in Pparanull mice Body weights in the wild-type mice on a MFD increased gradually, but there was no significant difference among the four groups (Figure 1a) . However, in the Ppara-null mouse group, by the 5th week, the MFD group body weights increased more than the other three groups. At the end of treatment, the body weights of the KO-MFD group increased by 46%, which was significantly higher than those of the other three groups (31% for KO-Con, 34% for KO-MFD-G and 32% for KO-MFD-F) (Figure 1b) . Glucose tolerance test revealed that the blood glucose uptake was similar among the four wild-type groups (Figure 1c) . However, in Ppara-null mice, the serum glucose level at 30 min after the glucose challenge in the KO-MFD group was significantly higher than that in the control group (21.6 AE 3.08 mmol/l vs 14.9 AE 1.6 mmol/l). Those in the KO-MFD-G and KO-MFD-F groups were almost normalized (16.8 AE 1.58 and 16.6 AE 2.1 mmol/l). At the other three time points (0, 60 and 120 min), no significant differences were observed among the four Ppara-null groups (Figure 1d) .
Serum TC and TG were not changed in the WT-MFD, WT-MFD-G and WT-MFD-F groups in comparison with the wild-type mouse control group. In Ppara-null mice, the TC and TG in the KO-MFD group were increased by 0.9-fold and 0.14-fold, respectively. In the KO-MFD-G mice, the TC and TG were lowered by 54% and 29% compared with the KO-MFD group. In the KO-MFD-F mice, TC and TG levels were lowered by 58% and 38%, respectively (Figure 1e and 1f) .
Histopathology of hepatic and adipose tissues
The liver index in wild-type mice was increased by fibrate treatment, and no modification was observed in Ppara-null mice (Figure 2a and 2b) . For the hepatic lipid levels, there were no obvious differences among the four groups in the wild-type mice for both TG and TC. In the Ppara-null mice, the TC and TG were increased by 1.73-fold and 3.1-fold, respectively, in the KO-MFD groups. By contrast, they were decreased by 50%, 40% in KO-MFD-G and 29%, 33% in KO-MFD-F group. This tendency was the same as that of the serum lipid, fatty liver and the pathological observations (Figure 2c and 2d) . These data accorded with the histopathological results. In the wild-type groups, there was no difference among the four groups. In the KO mice, the KO-MFD group exhibited more fat vacuoles than the WT-MFD group, suggesting the occurrence of fatty liver. This was significantly attenuated in the KO-MFD-G and KO-MFD-F groups (Figure 3 ).
In the adipose tissues, the volume of the fat cells in adipose tissues was much larger and the shape was more irregular than in the KO-MFD mice. In KO-MFD-G and KO-MFD-F treated with the gemfibrozil and fenofibrate, the size modification of fat cells was normalized, similar to the tendency of the above fat vacuoles (Figure 4) . For the fat cell diameter, there was no difference among wild-type groups, but it was increased by 1.41-fold in KO-MFD, which is higher than that in the KO-MFD-G and KO-MFD-F (0.41-fold, 0.28-fold) (Figure 5a and 5b) . Similarly, the adipose indexes among the four wild-type groups were not different from each other (Figure 5c ). However, in the Ppara-null mice MFD group, it was increased by 2.14-fold, much higher than that in the KO-MFD-G (0.50-fold) and KO-MFD-F (0.52-fold), showing the same tendency as that of the body weight (Figure 5d ).
Inflammation in hepatic and adipose tissues was inhibited by fibrates
Tnfa, Srebf1 and Icam1 are pro-inflammatory factors, which were often used to explore the inflammation status. [31, 32] In the liver tissues, the Tnfa, Srebf1 and Icam1 mRNA levels showed no difference between the wildtype mice and the Ppara-null mice indicating no extensive inflammation in the liver tissue associated with MS ( Figure 6a, 6c and 6e) . In adipose tissues of the wildtype mice, no modification of Tnfa, Srebf1 and Icam1 mRNAs was observed. However, in Ppara-null mice, Tnfa, Srebf1 and Icam1 mRNAs in the KO-MFD group were increased by 6.6-fold, 7.7-fold and 7.6-fold, respectively, compared with the control group. In the KO-MFD-G and KO-MFD-F groups, these increases were attenuated and some were normalized (Figure 6b, 6d  and 6f) .
In wild-type mice, the expression of three PPARa target gene mRNAs (Ehhadh, Cyp4a10 and Acox1) was increased by 47-fold, 34-fold and 8.6-fold in WT-MFD-G and 54-fold, 39-fold and 4.4-fold in WT-MFD-F mice. In contrast, no change in the WT-Con and WT-MFD groups was observed. In Ppara-null mice, none of these PPARa target genes was activated among the four groups ( Figure S1 ). So the above phenotype modifications and fibrate actions in Ppara-null mice were independent of PPARa. 
STAT3 pathway mediates MS development and the actions by fibrates
The expression of Socs3, Fga and Fgb was very specifically regulated by STAT3 pathway and was considered as STAT3 target genes to indicate the activation of this pathway. [33] In the liver tissues of the wild-type mice, there was no obvious difference in the Socs3, Fga and Fgb mRNA levels among the four groups. In the Ppara-null mice, Socs3 mRNA in the KO-MFD group was increased by 5.7-fold compared with the control group. Fga and Fgb mRNAs were increased by 2-fold and 4.7-fold, respectively, suggesting slight activation of the STAT3 pathway (Figure 7a, 7c  and 7e) . In adipose tissue, the Socs3, Fga and Fgb mRNAs were not changed in the WT-HF, WT-MFD-G and WT-MFD-F groups, suggesting that the STAT3 pathway was not activated in the wild-type mice. In Ppara-null mice, Socs3, Fga and Fgb mRNAs were increased by 10.3-fold, 7.4-fold and 13.5-fold, respectively, in the KO-MFD group.
In the KO-MFD-G group, Socs3, Fga and Fgb mRNAs were decreased by 56%, 52% and 70%, respectively, and in KO-MFD-F group, they were decreased by 81%, 73% and 89%, respectively, indicating that the STAT3 pathway was strongly activated by MFD but inhibited by gemfibrozil and fenofibrate ( Figure 7b, 7d and 7f) . Western blot analysis of the liver tissues revealed that the p-STAT3 pathway was not activated in livers of the wild-type groups. In Ppara-null mice, activation of p-STAT3 was clearly observed in the KO-MFD group. The inhibition was also observed in the KO-MFD-G and KO-MFD-F groups. In adipose tissue, the p-STAT3 pathway was not activated in the wild-type mice, but was significantly activated in the Pparanull mice, and inhibited in the KO-MFD-G and KO-MFD-F mice (Figure 8 ). The NF-jB and JNK inflammatory pathways were also examined, but no activation was observed among the four groups in either mouse line ( Figure S2) .
In 3T3-L1 adipogenic stem cells, Stat3 siRNA decreased the expression of STAT3 induced by the high-glucose 
Discussion
Presently, MS cannot be effectively treated with a single agent in the clinic. Physical exercise and diet control are the main strategies for MS prevention. The clinical agents including antihypertensive drugs, thiazolidinediones, sulfonylureas, statins and fibrates have been used to treat individual MS symptom in single or combination therapy. [34] However, this treatment strategy increased the risk of side effects and drug-drug interactions. [1] Besides the action on lipid metabolism, fibrates were effective for improving glucose metabolism and decreasing blood pressure. In this study, gemfibrozil and fenofibrate were found to be effective for preventing MS development in the Ppara-null mouse model, as indicated by the inhibitory effects on the body weight, glucose tolerance, serum TG and TC, as well as the inflammation. This action of fibrates suggested their therapeutic potential for patients with high risk of MS development, independent of PPARa.
Few studies could be found regarding simultaneous treatment of all MS symptoms by fibrates. Most studies only investigated the effect against single MS symptom, and their doses were designed based on clinical application (100 mg bid or tid, or 100-200 mg/kg). [35] [36] [37] In this study, gemfibrozil (0.375%) and fenofibrate (0.075%) were found to be effective against MS development. This dose was only 1/3-1/2 of the clinical dose level by comparing the trough concentration between mouse model and the clinical data. [38] Risk of adverse reactions would be considerably decreased if this low dose is proven to be effective as well in the clinic. So the dose-effect relationship found in this study was quite clinical relevant.
High-fat diet (60% kcal fat) is the typical diet used to induce metabolic disease in mouse models. [27, 39] Sex difference, baseline fat mass and calorie levels (10% and 45% kcal fat) also affect body weight. [40] The reported roles of PPARa in development of MS symptoms under different treatment regimens were not the same. In a Sv/ 129 mouse model treated with HFD containing 27% safflower oil (59% kcal fat), the impaired insulin resistance in Ppara-null mice was twice that of wild-type mice. [41] However, in C57BL/6N mice fed a diet enriched with hydrogenated coconut oil, hyperinsulinaemia was observed in wild-type mice, but not in Ppara-null mice. [27] In this study, the MFD exhibited discriminative power between two mouse lines in a 3-month study.
Only Ppara-null mice developed MS as indicated by the changes in body weight, glucose tolerance, and serum and hepatic lipids. These responses were not observed in wild-type mice, supporting the view that PPARa is a protective factor in MS development. However, it remains to be investigated whether the different roles of PPARa in MS development are related with nutrition, genetic background or other unknown factors. In C57BL/6 mice fed high-fat diet, the hyperinsulinaemia was lowered by the PPARa activator fenofibrate and ciprofibrate. [20] In Zucker diabetic fatty rats treated with fenofibrate, the insulin responses were improved. [18] These study illustrated the activation of PPARa can protect the MS symptom development. In Ppara-null mice and wildtype (C57BL/6N) mice treated with cholic acid, the bile acid homeostasis was disrupted in Ppara-null mice, indicating the protective role of basal PPARa. [42] In mice treated with ANIT, the liver inflammation was lower in wild-type compared with that in Ppara-null mice, also suggesting the protective function of basal PPARa. [30] In mice fed a diet enriched with hydrogenated coconut oil, hyperinsulinaemia was observed in wild-type mice, but not in Ppara-null mice. [27] In Ppara-null mice treated with HFD, the insulin sensitivity, blood pressure and intimal lesion were all improved. [28] In these studies, PPARa knockout became protective. Thus, the role of PPARa in MS development was controversial. In this study, all the results in the MFD groups of two mouse lines indicated that the basal PPARa played a protective role against MS development. STAT3 plays a key role in body weight regulation and glucose homeostasis. Disruption of mouse neural STAT3 caused obesity, diabetes and thermal dysregulation. [43] In liver tissues of STAT3-deficient mice, insulin resistance was associated with increased expression of gluconeogenic genes. Restoration of hepatic STAT3 corrected the metabolic abnormalities and the alterations of hepatic expression of these genes. [44] Mice with an adipocyte-specific disruption of the STAT3 displayed increased adiposity and adipocyte hypertrophy, indicating a role for STAT3 in regulating body weight homeostasis. [45] In this study, by screening the inflammation pathway-associated MS, no activation of NF-jB and JNK pathways was observed. Only STAT3 activation, its target gene expression and the inflammation in hepatic and adipose tissues correlated well with the MS symptoms between the wild-type and Ppara-null mice, or among the four Ppara-null groups. The other proinflammatory pathways analysed did not respond in any group of the two mouse lines. In 3T3-L1 adipogenic stem cells, Stat3 knockdown caused a decrease in lipid-containing droplets. Thus, it was quite reasonable to suppose the contributing role STAT3 signalling in MS development.
Fibrate effects for dyslipidaemia were classically considered dependent on PPARa; however, PPARa-independent actions were reported recently. In streptozotocin-induced diabetic apolipoprotein-deficient mice receiving gemfibrozil, the anti-atherogenic action was found to be independent of changes in cholesterol and glucose metabolism. [24] In isolated mouse aortas and middle cerebral arteries, the tension of middle cerebral arteries was inhibited by GW7647, WY14643 and gemfibrozil. But it was negative in PPARadeficient mice, demonstrating that actions were PPARaindependent. [46] In mice treated with a PPARa activator, the smooth muscle cell proliferation, tissue factor expression and neointimal formation were observed only in Ppara-null mice. [47] In this study, MS symptoms developed in Pparanull mice and they were inhibited by low dose of gemfibrozil and fenofibrate, respectively. These data suggested that the PPARa-independent mechanism of fibrate agents might be as important as the PPARa-dependent mechanisms, in agreement with previous reported viewpoint. [48] One might suspect the clinical relevance of this study because wild-type mouse did not develop MS and the effect could not be validated for clinical scenario. It usually took 3-6 months to induce MS using HFD in rodent models. [7, 8] This study not only found the PPARa-independent action against MS by fibrates, but also revealed the differentiation potential of MFD in wild-type and Ppara-null mice suggesting different sensitivity of tow mouse lines. If stronger or longer induction was challenged to wild-type mice, they were expected to develop MS and the effect of fibrates in this study would be probably observed. Fibrates will act against MS development when risk factors exist in the clinic, because the action was independent of PPARa ( Figure S3 ). 
Conclusion
Conclusively, wild-type and Ppara-null mice were treated with fibrates to investigate the action of fibrates on MS with the underlying mechanism being explored. The data suggested a protective role for PPARa against MS development via inhibition of STAT3 signalling. More importantly, low dose of clinical fibrate gemfibrozil and fenofibrate could inhibit MS development independent of PPARa. Considering the species-related difference in PPARa, investigations are warranted to prove this action of fibrates for clinical therapeutics.
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